Clinical trials
Hematology clinical trials
Below are recruiting hematology clinical trials, each written for real people, not researchers. We’re tracking 602 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05477563RecruitingPhase 3
One-time gene therapy for severe sickle cell and transfusion anemia
This trial tests a single dose of gene therapy (CTX001) to improve outcomes for people with severe sickle cell disease or transfusion-dependent beta-thalassemia. It aims to see how well it works and whether it is safe, especially after a planned stem cell transplant process.
New York, New YorkAges 12–35 - NCT05488548RecruitingPhase 1
Study drug that blocks BET and CBP/p300 in advanced cancers
This Phase 1 trial tests an investigational medicine that targets BET and CBP/p300 to try to slow or control advanced, hard-to-treat cancers. You may be eligible if you have certain prostate cancer or NUT midline carcinoma, or specific blood cancers like CMML or myelofibrosis (MF), and your body functions are strong enough for chemotherapy-style treatment.
Phoenix, ArizonaAges 18 years+ - NCT05518383RecruitingPhase 4
Pediatric B-cell lymphoma treatment study using established care
This trial studies treatment for children and teens with certain B-cell non-Hodgkin lymphomas using a specific treatment protocol. It may help doctors confirm how well the regimen works in young patients and improve care over time.
Moscow, RFAges 1 day–18 years - NCT05529069RecruitingPhase 2
Testing pirtobrutinib plus venetoclax for relapsed mantle cell lymphoma
This Phase 2 trial tests how well the combination of pirtobrutinib and venetoclax works for people with mantle cell lymphoma that has come back or did not respond to treatment. It’s meant to help shrink the lymphoma and improve outcomes after prior therapies.
Houston, TexasAges 18 years+ - NCT05556928Recruiting
Cancer and aging study for adults with blood cancers
This study builds a registry to learn how aging and “resilience” relate to outcomes in people with blood cancers. You may be asked to complete questionnaires during UAB visits, which can help researchers better understand needs in older adults.
Birmingham, AlabamaAges 50 years+ - NCT05573802RecruitingPhase 1/Phase 2
Belantamab and other medicines for new multiple myeloma
This early-phase study tests how safe and effective belantamab mafodotin is when combined with lenalidomide and dexamethasone, plus a medicine called nirogacestat, in people with newly diagnosed multiple myeloma who cannot have stem cell transplant. It may help shrink the cancer and improve outcomes, while doctors track side effects.
AthensAges 18 years+ - NCT05598879Recruiting
New heart-cancer visit registry for adults
This study is a “registry,” meaning it collects health information from adults who are getting a new heart (cardio) evaluation related to cancer. It helps doctors better understand heart risks and care needs for different cancer types and treatments.
Weston, FloridaAges 18 years+ - NCT05618041Recruiting
CAR-T treatment trial for relapsed or hard-to-treat blood cancers
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
Taiyuan, ShanxiAges 14–75 - NCT05630651Recruiting
ZS801 for adults with severe hemophilia B
This trial studies ZS801, a gene therapy, in adults with hemophilia B who have very low natural FIX (a clotting protein) and frequent bleeding or joint problems. It aims to see how well it works and whether it is safe, especially by monitoring blood counts, infections, and immune responses.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT05641610RecruitingPhase 1/Phase 2
Study drug for adults with hemophilia B who still bleed
This Phase 1/2 study tests ZS801, a gene-related treatment, to see how safe it is and whether it helps prevent bleeding in adults with hemophilia B. You may be considered if you’ve had frequent bleeds or joint problems and meet several lab and health requirements.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05658640RecruitingPhase 1/Phase 2
Testing trametinib and steroid plus chemo for relapsed blood cancers
This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.
ViennaAges 1–21 - NCT05660473RecruitingPhase 2
Study of venetoclax plus chemotherapy for Ph-negative ALL
This Phase 2 trial tests whether adding venetoclax to a chemotherapy plan works better for Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL). It may help people achieve deeper remission by targeting leukemia cells in a different way than chemotherapy alone.
TianjinAges 14–60 - NCT05694806Recruiting
CT scan study for blood cancers with a chest mass syndrome
This study looks at how CT scan findings in the chest (mediastinum) can relate to outcomes for people with blood cancers who have mediastinal mass syndrome. It may help doctors better understand which scan features matter most when deciding care in the ICU.
ToulouseAges 16 years+ - NCT05707325RecruitingEarly Phase 1
Testing a lab-made red blood cell treatment for advanced cancers
This early trial studies whether an engineered (lab-made) red blood cell treatment is safe and tolerable, and whether it may show early anti-cancer activity. It may help people with advanced cancers whose disease has not responded well to standard options.
Hangzhou, ZhejiangAges 18–75 - NCT05709288RecruitingPhase 1
Gene therapy for teens with hemophilia B
This Phase 1 study tests a one-time gene therapy treatment (BBM-H901) for boys ages 12 to 18 with hemophilia B. It aims to see if the treatment is safe and can help the body make more clotting factor over time.
Tianjin, Tianjin MunicipalityAges 12–18 - NCT05724121Recruiting
Study heart rhythm changes during BTK or venetoclax treatment
This observational study tracks how your heart rhythm (heartbeat pattern) changes while you take a BTK inhibitor or venetoclax. It may help doctors better understand heart rhythm risks in people receiving these cancer-related medicines.
Bethesda, MarylandAges 18–110 - NCT05728658RecruitingPhase 1
Study of ICP-248 for relapsed or refractory B-cell cancers
This early-phase (Phase 1) study tests ICP-248 in people with certain B-cell cancers that have come back (relapsed) or did not respond to prior treatment (refractory). The goal is to learn the safest dose and whether it can help shrink or control the cancer.
Bengbu, AnhuiAges 18–80 - NCT05745714RecruitingPhase 1/Phase 2
Targeted triple-combination treatment for children with relapsed blood cancers
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
ViennaAges 1–21 - NCT05751044RecruitingPhase 1/Phase 2
Study of four medicines for children with difficult blood cancers
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
ViennaAges 1–21 - NCT05768269Recruiting
Follow-up study for people previously treated with cellular therapy
This trial follows up with people who already received a Century Therapeutics cellular therapy treatment. It mainly checks how you’re doing over time and whether the treatment has lasting effects.
Gilbert, ArizonaAges 18 years+ - NCT05779605Recruiting
Online rehab for lymphoma survivors after chemotherapy
This trial tests a telerehabilitation (remote exercise/rehab) program for people with recent lymphoma or other blood cancers after chemotherapy. It aims to improve recovery and fitness while monitoring safety through an exercise test and check-ins.
BrnoAges 18 years+ - NCT05794880Recruiting
Immunotherapy lowering immune cells before transplant in children
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
Milwaukee, WisconsinAges birth–25 years - NCT05805605RecruitingPhase 2
Low-intensity stem cell transplant with donor cells and blood-protection
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
Minneapolis, MinnesotaAges Up to 75 years - NCT05807789Recruiting
Genetic testing during CAR-T treatment for adults
This study looks at a patient’s genetic (molecular) information while they receive CAR-T cell therapy. The goal is to better understand how different biological factors may affect CAR-T treatment.
Bologna, ItalyAges 18–70
Hear when a new Hematology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematology?
- Yes. Clin2 currently lists 602 recruiting hematology studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematology trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematology trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.